Bausch Health Cos Free Cash Flow 2011-2025 | BHC

Bausch Health Cos free cash flow from 2011 to 2025. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
Bausch Health Cos Annual Free Cash Flow
2024 1,260.00
2023 817.00
2022 -946.00
2021 1,826.00
2020 830.00
2019 1,276.00
2018 1,378.00
2017 5,372.00
2016 2,051.00
2015 2,035.00
2014 3,512.00
2013 967.80
2012 641.00
2011 617.96
2010 261.41
Bausch Health Cos Quarterly Free Cash Flow
2025-09-30 600.00
2025-06-30 286.00
2025-03-31 96.00
2024-12-31 1,260.00
2024-09-30 765.00
2024-06-30 431.00
2024-03-31 129.00
2023-12-31 817.00
2023-09-30 525.00
2023-06-30 285.00
2023-03-31 107.00
2022-12-31 -946.00
2022-09-30 -1,355.00
2022-06-30 -38.00
2022-03-31 -109.00
2021-12-31 1,826.00
2021-09-30 1,880.00
2021-06-30 735.00
2021-03-31 381.00
2020-12-31 830.00
2020-09-30 495.00
2020-06-30 341.00
2020-03-31 210.00
2019-12-31 1,276.00
2019-09-30 1,119.00
2019-06-30 676.00
2019-03-31 391.00
2018-12-31 1,378.00
2018-09-30 1,119.00
2018-06-30 591.00
2018-03-31 397.00
2017-12-31 5,372.00
2017-09-30 4,657.00
2017-06-30 1,147.00
2017-03-31 916.00
2016-12-31 2,051.00
2016-09-30 1,525.00
2016-06-30 988.00
2016-03-31 495.00
2015-12-31 2,035.00
2015-09-30 1,498.90
2015-06-30 789.00
2015-03-31 425.30
2014-12-31 3,512.00
2014-09-30 2,747.60
2014-06-30 688.70
2014-03-31 426.20
2013-12-31 967.80
2013-09-30 737.80
2013-06-30 561.00
2013-03-31 249.70
2012-12-31 641.00
2012-09-30 583.84
2012-06-30 463.37
2012-03-31 222.36
2011-12-31 617.96
2011-09-30 443.13
2011-06-30 279.01
2011-03-31 64.83
2010-12-31 261.41
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.466B $9.625B
Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $27.493B 9.29
BridgeBio Pharma (BBIO) United States $11.909B 0.00
Dr Reddy's Laboratories (RDY) India $11.238B 16.62
Supernus Pharmaceuticals (SUPN) United States $2.580B 21.61
Amphastar Pharmaceuticals (AMPH) United States $1.117B 7.96
Taysha Gene Therapies (TSHA) United States $1.049B 0.00
Personalis (PSNL) United States $0.615B 0.00
Assembly Biosciences (ASMB) United States $0.239B 0.00
Sol-Gel Technologies (SLGL) Israel $0.085B 0.00
Evoke Pharma (EVOK) United States $0.017B 0.00
Teligent (TLGT) United States $0.000B 0.00